Case Studies & Customer Stories

Streamlining Antibody Capture with Multi-Column Chromatography

The Challenge — Traditional batch chromatography, while widely used, presents limitations such as high resin costs, underutilization of resin capacity, and a less-than-ideal footprint. These challenges can significantly impact the development and production of new therapies, especially for small to medium-sized biotech companies.

Boosting Yield: Upgrading from Thermo SUB to Cytiva XDR

The Challenge — Transition the upstream bioprocess of cell culture from the Thermo Single-Use Bioreactor (SUB) to the Cytiva Xcellerex Disposable Reactor (XDR) for two different antibody products. This strategic move was essential to meet increasing production demands while ensuring process integrity and quality were not compromised.

Solving HCP Co-Elution Issues with Cell Line Engineering

The Challenge — During cell line development for a therapeutic protein, AGC Biologics found that a CHO host cell protein was bound to and co-eluted with the product. Host cell engineering removed a host cell impurity, eliminating customized downstream purification, simplifying the process, and reducing costs.

Reducing Costs in Biologics Manufacturing with a Fed-Batch Approach

The Challenge — A biopharmaceutical client faced significant challenges in scaling up production to meet commercial demands. While their initial small-scale manufacturing process utilizing perfusion technology proved effective, the company recognized the need for a more efficient and scalable manufacturing strategy to ensure the successful commercialization of their therapeutic protein. Learn how AGC Biologics crafted a strategy to enhance productivity and significantly reduce costs, making the drug more accessible to patients.

Robust, Scalable Manufacturing

N-Linked Glycan Analysis for Complex Glycoproteins

The Challenge — The client had an established cell line and process for a complex glycoprotein that produced high-quality material but had a low yield and was not scalable. With plans to move into clinical development, AGC Biologics was challenged to develop a robust, scalable manufacturing process for this molecule while addressing the unique project parameters and production requirements. 

Get Your Antibody Produced on Time

The Challenge — Accelerating the development and manufacture of monoclonal antibodies is critical for reducing the time it takes to move a promising therapy from bench to clinic. Learn how AGC Biologics can deliver the needed quantities of cGMP monoclonal antibodies within your deadlines.